Sigma Healthcare updated FY20 EBITDA Guidance

  • Dec 14, 2019 AEDT
  • Team Kalkine
Sigma Healthcare Limited (ASX:SIG) announced the FY20 EBITDA guidance after the announcement on new first-line agreement with My Chemist/Chemist Warehouse Group (MC/CW Group). The new agreement will lift the annualised sales by $700 - $800 million when at a full run rate, which is expected to be from 1 July 2020. The company predicted the FY20 EBITDA of approximately $46-47 million which includes $57-58 million benefits from the adoption of new accounting standards (AASB 16 Leases). The company’s FY21 growth is expected to accelerate from both the core business and MC/CW Group. On 13 December 2019, the stock traded higher by 3.9%, at $0.660, relative to the previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK